Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Researchers demonstrate with a selection of clinical phenotypes and treatment variables, a statistically useful and biologically meaningful gene signature of Papillary thyroid carcinoma prognosis, which may be developed as a biomarker to help prevent overdiagnosis.
Investigators introduce a comprehensive algorithm that incorporates chromatin, position, and sequence features to accurately predict highly effective single guide RNAs (sgRNAs) for targeting nuclease-dead Cas9-mediated transcriptional repression (CRISPRi) and activation (CRISPRa).
DNA methylation enzyme EZH2 may be a potential epigenetic target for lung cancer treatment.
ZEB1-induced EMT and associated molecular changes in ESRP1 and CD44 contribute to early pathogenesis and metastatic potential in established lung cancer. TGF-β, VDR signaling and CD44 splicing pathways associated with ZEB1 are potential EMT chemoprevention and therapeutic targets in NSCLC.
Researchers present an unrecognized role of sialic acid metabolism and protein sialylation in regulating the expression of genes that maintain breast cancer pathogenicity.
Researchers discuss combined targeting of the EGFR effector AKT and the glutathione antioxidant pathway mimicked Nrf2 ablation to potently inhibit pancreatic cancer ex vivo and in vivo, representing a promising synthetic lethal strategy for treating the disease.
Researchers at UCSF have identified Pannexin 3 as a candidate gene that links body mass index (BMI) and carcinogenesis.